AstraZeneca’s Withdrawal Plan and Implications for Chronic Heart Failure and Kidney Failure Treatments

재원 : Industry sources revealed on April 8th that AstraZeneca and HK inno.N are in the process of transferring approval for chronic heart failure and kidney failure indications, in addition to diabetes, to HK inno.N. This move precedes AstraZeneca's withdrawal plan for Farxiga (active ingredient: Dapagliflozin) in Korea. By providing safety and efficacy assessment data, it is anticipated that HK inno.N's product will gain approval for these indications.

카지노 : Farxiga, initially approved as a second-line treatment for type 2 diabetes in 2013, gained additional indications for chronic heart failure in 2020 and chronic kidney failure in 2021 in South Korea. However, reimbursement was limited to diabetes treatment until February 2024 when it was extended to non-diabetic chronic heart failure patients. AstraZeneca had already decided to withdraw from the Korean market before this expansion.

The concern arises from potential price reductions in South Korea due to generic releases, impacting other countries. Despite scheduled price reduction, Farxiga's price remains at the existing cap due to an execution suspension.